Work

Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial

Year: 2021

Type: article

Study design: Clinical Trial

Source: The Lancet Respiratory Medicine

DOI: 10.1016/s2213-2600(21)00167-3

Authors: Klaus F Rabe, Bartolome R Celli, Michael E Wechsler, Raolat M Abdulai, Xiaodong Luo, Maarten M Boomsma, Heribert Staudinger, Julie E Horowitz, Aris Baras, Manuel A Ferreira, Marcella K Ruddy, Michael C Nivens, Nikhil Amin, David M Weinreich, George D Yancopoulos, Helene Goulaouic

Institutions: Christian-Albrechts-Universität zu Kiel, German Center for Lung Research, LungenClinic Grosshansdorf, Brigham and Women's Hospital, Harvard University, National Jewish Health, Sanofi (United States), Sanofi (Netherlands), Regeneron (United States), Sanofi (France)

Language: English

Topic: Chronic Obstructive Pulmonary Disease (COPD) Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W3185379947

FWCI: 19.08

Cites: 40

Cited by: 233

Related to: 10